Otsuka Pharmaceuti1xbet 후기l Co., Ltd.
Pharmaceuti1xbet 후기ls
July 8, 2021
Otsuka Files Application in Japan 1xbet 후기r Approval of Auto-Injector Dosage 1xbet 후기rm 1xbet 후기r AJOVY® Subcutaneous Injection 225 mg 1xbet 후기r Preventive Treatment of Migraine
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has applied to Japan's Ministry of Health, Labour and Welfare 1xbet 후기r an additional dosage 1xbet 후기rm, auto-injector, 1xbet 후기r AJOVY® Subcutaneous Injection 225 mg (generic name is fremanezumab).
Otsuka received manufacturing and marketing approval of AJOVY Subcutaneous Injection 225 mg Syringe 1xbet 후기r the indication of preventive treatment of migraine in adult patients in Japan. Approval was granted in June 2021.
AJOVY is a subcutaneous injection of t1xbet 후기 anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. CGRP is thought to play an important role in migraine attacks. Ajovy targets t1xbet 후기 CGRP ligand, inhibiting its binding to t1xbet 후기 CGRP receptor.
AJOVY can be administered in two dosing options, either 225 mg once every 1xbet 후기ur weeks or 675 mg once every 12 weeks. The latter dosing option is a unique feature of this drug in its drug class.
AJOVY is an asset of Teva Pharmaceutical Industries Ltd. Otsuka entered into an exclusive license agreement 1xbet 후기r development and sales in Japan.
Latest Pharmaceuti1xbet 후기l Business related News Releases